Home » Stock Symbols » DPH.L

Dechra Pharmaceuticals plc

DPH.L: Share Price & Live Data

-38.00 (-1.34%)
Price open 2,866.00
Previous close 2,838.00
Market cap 2.88B
Volume 136.18K
Day high 2,866.00
Day low 2,794.00
Year high 3,090.00
Year low 2,336.00

About Dechra Pharmaceuticals plc

Dechra Pharmaceuticals plc. Is a pharmaceutical company that develops, manufactures and markets veterinary pharmaceutical products worldwide. Founded in 1997 by way of a buyout from Lloyds Chemist. The company has operations in Europe as well as North America in addition to running a pharmaceutical research center.

The company’s pipeline of pharmaceuticals is made up of products for endocrinology, dermatology analgesia, and other critical care products for dogs and cats and poultry vaccines. The company bought Danish veterinary product business VetXX for £62 million in 2007. In 2013, it divested its veterinary service business to Patterson Companies for £87.5 million.

Dechra Pharmaceuticals plc. is also engaged in the production and distribution of pet nutrition products. It also develops manufactures and regulates crop production.

Dechra Pharmaceuticals plc. went public in 2000 and was listed on the London Stock Exchange.

Latest Dechra Pharmaceuticals plc News

FTSE 100 Index – An Overview Of Friday, October 18th, 2019

Following yesterday’s announcement that Brexit deal has been finalized in the European Union Summit (EU summit), the celebration in the FTSE 100 index was quite evident. The market made a daily high of 7,237.78. While significant gains were still lost towards the end of the day with DUP of Northern Ireland making a statement that it plans...

UPDATE: Dechra Pharmaceuticals Ups Dividend As Interim Profit Rises

Veterinary pharmaceutical business Dechra Pharmaceuticals PLC Monday raised its interim dividend as it posted a rise in pretax profit for its first half

Dechra Pharmaceuticals share price: Company Halts Development Of Feline Endocrine Drug

Dechra Pharmaceuticals PLC (LON:DPH) Friday reiterated confidence that the "execution of [its] strategy will continue to deliver growth", as it traded in line with expectations in its financial first quarter to end-September, and said it had terminated development of its feline endocrine drug.


Dechra Pharmaceuticals plc
London Stock Exchange
Drug Manufacturers—General
United Kingdom
Full time employees

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.